What is Morgan Stanley's price target for PRLD?

Morgan Stanley's latest stated price target for Prelude Therapeutics Incorporated (PRLD) is $4, from its action on Dec 19, 2023.

What is Morgan Stanley's rating on PRLD?

Morgan Stanley rates PRLD Underweight, a bearish rating, as of Dec 19, 2023.

When did Morgan Stanley last change its view on PRLD?

On Dec 19, 2023, Morgan Stanley downgrades to Underweight from Equal-Weight, price target $10 to $4.

Analyst firms · Morgan Stanley · PRLD

Morgan Stanley PRLD price target and rating history

Prelude Therapeutics Incorporated (PRLD) · Health Care

Morgan Stanley rates Prelude Therapeutics Incorporated (PRLD) Underweight with a $4 price target, as of its latest action on Dec 19, 2023. It has published 4 rating actions on PRLD since October 2021, including 2 upgrades and 2 downgrades.

Current rating: Underweight
Price target: $4
Median target, all firms: Too few
Actions on PRLD: 4

Morgan Stanley price target on PRLD

Morgan Stanley price target on PRLD, each point a stated target, October 2021 to December 2023.

Every Morgan Stanley rating on PRLD

Dec 19, 2023
DowngradeMorgan Stanley downgrades to Underweight from Equal-Weight, price target $10 to $4
Sep 9, 2022
DowngradeMorgan Stanley downgrades to Equal-Weight from Overweight, price target $19 to $11
Oct 11, 2021
UpgradeMorgan Stanley upgrades to Overweight from Equal-Weight, price target $60 to $35
Oct 8, 2021
UpgradeMorgan Stanley upgrades to Overweight from Equal-Weight

Questions about Morgan Stanley and PRLD

What is Morgan Stanley's price target for PRLD?: Morgan Stanley's latest stated price target for Prelude Therapeutics Incorporated (PRLD) is $4, from its action on Dec 19, 2023.
What is Morgan Stanley's rating on PRLD?: Morgan Stanley rates PRLD Underweight, a bearish rating, as of Dec 19, 2023.
When did Morgan Stanley last change its view on PRLD?: On Dec 19, 2023, Morgan Stanley downgrades to Underweight from Equal-Weight, price target $10 to $4.

More PRLD rating histories

All Morgan Stanley ratings PRLD news and filings Every analyst firm

From rating actions in the Quantisnow feed. A target holds until the firm states a new one; a reiteration with no target keeps the last one. Not investment advice.